Spots Global Cancer Trial Database for A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma

Official Title: A First-in-Human Clinical Trial of Pharmacologic Ascorbate and Ferumoxytol Combined With Concomitant Temozolomide and External Beam Radiation Therapy for Newly Diagnosed Glioblastoma

Study ID: NCT04900792

Conditions

Glioblastoma

Glioblastoma Multiforme

Interventions

Ferumoxytol injection

Pharmacological ascorbate

External beam radiation therapy

Temozolomide

Study Description

Brief Summary: This clinical trial evaluates adding ferumoxytol and pharamcologic ascorbate (vitamin C) to standard of care treatment of glioblastoma multiforme (a type of brain tumor) in adults. All subjects will receive ferumoxytol and pharmacologic ascorbate in addition to the standard treatment.

Detailed Description: The initial, standard treatment for glioblastoma multiforme (GBM) involves maximum safe surgical resection followed by radiation combined with temozolomide (a chemotherapy pill you take by mouth). Participants in this trial will: * receive intravenous (IV) ferumoxytol the day before starting radiation, then around radiation treatments 6, 25, and 31. * receive high doses of intravenous (IV) ascorbate three times a week during the combined radiation and chemotherapy phase. * provide feedback about how they feel and their quality of life. This is done through short surveys as well as discussing with the study team.